You are here

Cancer Med DOI:10.1002/cam4.262

FGFR3 expression in primary and metastatic urothelial carcinoma of the bladder.

Publication TypeJournal Article
Year of Publication2014
AuthorsGuancial, EA, Werner, L, Bellmunt, J, Bamias, A, Choueiri, TK, Ross, R, Schutz, FA, Park, RS, O'Brien, RJ, Hirsch, MS, Barletta, JA, Berman, DM, Lis, R, Loda, M, Stack, EC, Garraway, LA, Riester, M, Michor, F, Kantoff, PW, Rosenberg, JE
JournalCancer Med
Volume3
Issue4
Pages835-44
Date Published2014 Aug
ISSN2045-7634
KeywordsCarcinoma, Transitional Cell, Gene Dosage, Gene Expression, Humans, Kaplan-Meier Estimate, Mutation, Missense, Proportional Hazards Models, Receptor, Fibroblast Growth Factor, Type 3, RNA, Messenger, Urinary Bladder Neoplasms
Abstract

While fibroblast growth factor receptor 3 (FGFR3) is frequently mutated or overexpressed in nonmuscle-invasive urothelial carcinoma (UC), the prevalence of FGFR3 protein expression and mutation remains unknown in muscle-invasive disease. FGFR3 protein and mRNA expression, mutational status, and copy number variation were retrospectively analyzed in 231 patients with formalin-fixed paraffin-embedded primary UCs, 33 metastases, and 14 paired primary and metastatic tumors using the following methods: immunohistochemistry, NanoString nCounterTM, OncoMap or Affymetrix OncoScanTM array, and Gain and Loss of Analysis of DNA and Genomic Identification of Significant Targets in Cancer software. FGFR3 immunohistochemistry staining was present in 29% of primary UCs and 49% of metastases and did not impact overall survival (P = 0.89, primary tumors; P = 0.78, metastases). FGFR3 mutations were observed in 2% of primary tumors and 9% of metastases. Mutant tumors expressed higher levels of FGFR3 mRNA than wild-type tumors (P

DOI10.1002/cam4.262
Pubmed

http://www.ncbi.nlm.nih.gov/pubmed/24846059?dopt=Abstract

Alternate JournalCancer Med
PubMed ID24846059
PubMed Central IDPMC4303151